Advances Toward Engineering Functionally Mature Human Pluripotent Stem Cell-Derived β Cells

Human stem cell-derived β (SC-β) cells have the potential to revolutionize diabetes treatment through disease modeling, drug screening, and cellular therapy. SC-β cells are likely to represent an early clinical translation of differentiated human pluripotent stem cells (hPSC). In 2014, two groups ge...

Full description

Bibliographic Details
Main Authors:	Leonardo Velazco-Cruz, Madeleine M. Goedegebuure, Jeffrey R. Millman
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-07-01
Series:	Frontiers in Bioengineering and Biotechnology
Subjects:	stem cells diabetes differentiation pluripotent transplantation
Online Access:	https://www.frontiersin.org/article/10.3389/fbioe.2020.00786/full

id	doaj-4ec2b80bd10a4bdc837d437747074b1e
record_format	Article
spelling	doaj-4ec2b80bd10a4bdc837d437747074b1e2020-11-25T03:21:33ZengFrontiers Media S.A.Frontiers in Bioengineering and Biotechnology2296-41852020-07-01810.3389/fbioe.2020.00786557823Advances Toward Engineering Functionally Mature Human Pluripotent Stem Cell-Derived β CellsLeonardo Velazco-Cruz0Madeleine M. Goedegebuure1Madeleine M. Goedegebuure2Jeffrey R. Millman3Jeffrey R. Millman4Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St. Louis, MO, United StatesDivision of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St. Louis, MO, United StatesDepartment of Biomedical Engineering, Washington University in St. Louis, St. Louis, MO, United StatesDivision of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St. Louis, MO, United StatesDepartment of Biomedical Engineering, Washington University in St. Louis, St. Louis, MO, United StatesHuman stem cell-derived β (SC-β) cells have the potential to revolutionize diabetes treatment through disease modeling, drug screening, and cellular therapy. SC-β cells are likely to represent an early clinical translation of differentiated human pluripotent stem cells (hPSC). In 2014, two groups generated the first in vitro-differentiated glucose-responsive SC-β cells, but their functional maturation at the time was low. This review will discuss recent advances in the engineering of SC-β cells to understand and improve SC-β cell differentiation and functional maturation, particularly new differentiation strategies achieving dynamic glucose-responsive insulin secretion with rapid correction to normoglycemia when transplanted into diabetic mice.https://www.frontiersin.org/article/10.3389/fbioe.2020.00786/fullstem cellsdiabetesdifferentiationpluripotenttransplantation
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Leonardo Velazco-Cruz Madeleine M. Goedegebuure Madeleine M. Goedegebuure Jeffrey R. Millman Jeffrey R. Millman
spellingShingle	Leonardo Velazco-Cruz Madeleine M. Goedegebuure Madeleine M. Goedegebuure Jeffrey R. Millman Jeffrey R. Millman Advances Toward Engineering Functionally Mature Human Pluripotent Stem Cell-Derived β Cells Frontiers in Bioengineering and Biotechnology stem cells diabetes differentiation pluripotent transplantation
author_facet	Leonardo Velazco-Cruz Madeleine M. Goedegebuure Madeleine M. Goedegebuure Jeffrey R. Millman Jeffrey R. Millman
author_sort	Leonardo Velazco-Cruz
title	Advances Toward Engineering Functionally Mature Human Pluripotent Stem Cell-Derived β Cells
title_short	Advances Toward Engineering Functionally Mature Human Pluripotent Stem Cell-Derived β Cells
title_full	Advances Toward Engineering Functionally Mature Human Pluripotent Stem Cell-Derived β Cells
title_fullStr	Advances Toward Engineering Functionally Mature Human Pluripotent Stem Cell-Derived β Cells
title_full_unstemmed	Advances Toward Engineering Functionally Mature Human Pluripotent Stem Cell-Derived β Cells
title_sort	advances toward engineering functionally mature human pluripotent stem cell-derived β cells
publisher	Frontiers Media S.A.
series	Frontiers in Bioengineering and Biotechnology
issn	2296-4185
publishDate	2020-07-01
description	Human stem cell-derived β (SC-β) cells have the potential to revolutionize diabetes treatment through disease modeling, drug screening, and cellular therapy. SC-β cells are likely to represent an early clinical translation of differentiated human pluripotent stem cells (hPSC). In 2014, two groups generated the first in vitro-differentiated glucose-responsive SC-β cells, but their functional maturation at the time was low. This review will discuss recent advances in the engineering of SC-β cells to understand and improve SC-β cell differentiation and functional maturation, particularly new differentiation strategies achieving dynamic glucose-responsive insulin secretion with rapid correction to normoglycemia when transplanted into diabetic mice.
topic	stem cells diabetes differentiation pluripotent transplantation
url	https://www.frontiersin.org/article/10.3389/fbioe.2020.00786/full
work_keys_str_mv	AT leonardovelazcocruz advancestowardengineeringfunctionallymaturehumanpluripotentstemcellderivedbcells AT madeleinemgoedegebuure advancestowardengineeringfunctionallymaturehumanpluripotentstemcellderivedbcells AT madeleinemgoedegebuure advancestowardengineeringfunctionallymaturehumanpluripotentstemcellderivedbcells AT jeffreyrmillman advancestowardengineeringfunctionallymaturehumanpluripotentstemcellderivedbcells AT jeffreyrmillman advancestowardengineeringfunctionallymaturehumanpluripotentstemcellderivedbcells
_version_	1724613958173720576

Advances Toward Engineering Functionally Mature Human Pluripotent Stem Cell-Derived β Cells

Similar Items